Water-soluble N-2-Hydroxypropyl trimethyl ammonium chloride chitosan enhanced the immunogenicity of inactivated porcine parvovirus vaccine vaccination on sows against porcine parvovirus infection. 2020

Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
Engineering Research Center of Agricultural Microbiology Technology, Ministry of Education, Heilongjiang University, Harbinm, 150080, China; Key Laboratory of Microbiology, College of Heilongjiang Province, School of Life Science, Heilongjiang University, Harbin, 150080, China.

Porcine parvovirus (PPV) is one of the most common and important virus causes of infectious infertility in swine throughout the world. Inactivated PPV vaccine is broadly used, however, there is no appropriate immunomodulatory adjuvant for enhancing present vaccines and developing new ones. Therefore, in this study, the water-soluble N-2-Hydroxypropyl trimethyl ammonium chloride chitosan (N-2-HACC) was synthesized, the adjuvant potential of chitosan derivative was evaluated in inactivated PPV vaccine. Twenty adult healthy sows were assigned to four groups and vaccinated with synthesized PPV/N-2-HACC, commercial inactivated vaccine, N-2-HACC adjuvant and PBS. After insemination, all sows were challenged with the homologous PPV-H strain. In vivo immunization showed that sows immunized with the PPV/N-2-HACC induced more long-lasting HI antibodies and strong immune responses. Importantly, immunization of PPV/N-2-HACC significantly protected sows from homologous PPV-H strain infection. However, immunization of PPV/N-2-HACC didn't change the level of IL-2, IL-4 and IFN-γ and the production of CD4+, CD8 + T lymphocyte. The results indicated that PPV/N-2-HACC protect PPV infection mainly through enhancing the humoral immunity rather than cellular immunity. In addition, the mummified fetuses were observed from the control groups, but neither of the two vaccine groups. In conclusion, these results suggest that N-2-HACC can be exploited as an effective adjuvant for vaccine development, and the PPV/N-2-HACC are potent immunization candidates against PPV infection.

UI MeSH Term Description Entries
D010322 Parvoviridae Infections Virus infections caused by the PARVOVIRIDAE. Parvovirus Infections,Infections, Parvoviridae,Infections, Parvovirus,Infection, Parvoviridae,Infection, Parvovirus,Parvoviridae Infection,Parvovirus Infection
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011251 Pregnancy Complications, Infectious The co-occurrence of pregnancy and an INFECTION. The infection may precede or follow FERTILIZATION. Complications, Infectious Pregnancy,Infectious Pregnancy Complications,Maternal Sepsis,Pregnancy, Infectious Complications,Sepsis during Pregnancy,Sepsis in Pregnancy,Infectious Pregnancy Complication,Pregnancy Complication, Infectious,Sepsis in Pregnancies,Sepsis, Maternal
D005260 Female Females
D005317 Fetal Growth Retardation Failure of a FETUS to attain expected GROWTH. Growth Retardation, Intrauterine,Intrauterine Growth Retardation,Fetal Growth Restriction,Intrauterine Growth Restriction
D000071497 Immunogenicity, Vaccine The capacity of VACCINES to stimulate the ADAPTIVE IMMUNE RESPONSE to produce antibodies and antigen-specific T-CELL responses. It is typically measured in vaccinated individuals in observational studies setting. Antigenicity, Vaccine,Vaccine Antigenicity,Vaccine Immunogenicity
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
September 2021, Vaccines,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
November 2022, International journal of biological macromolecules,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
September 2015, International journal of biological macromolecules,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
April 2004, International journal of biological macromolecules,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
February 2008, European journal of medicinal chemistry,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
September 2016, Carbohydrate polymers,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
September 2022, International journal of biological macromolecules,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
November 2022, International journal of biological macromolecules,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
January 2020, Materials science & engineering. C, Materials for biological applications,
Mo Zhou, and Wanying Qu, and Yanwei Sun, and Lin Liang, and Zheng Jin, and Shangjin Cui, and Kai Zhao
September 2017, Carbohydrate polymers,
Copied contents to your clipboard!